GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Pyridam Farma Tbk (ISX:PYFA) » Definitions » EBIT

PT Pyridam Farma Tbk (ISX:PYFA) EBIT : Rp-97,517 Mil (TTM As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is PT Pyridam Farma Tbk EBIT?

PT Pyridam Farma Tbk's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was Rp-39,337 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was Rp-97,517 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PT Pyridam Farma Tbk's annualized ROC % for the quarter that ended in Sep. 2024 was 0.99%. PT Pyridam Farma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -7.26%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PT Pyridam Farma Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -1.85%.


PT Pyridam Farma Tbk EBIT Historical Data

The historical data trend for PT Pyridam Farma Tbk's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Pyridam Farma Tbk EBIT Chart

PT Pyridam Farma Tbk Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,047.38 31,788.06 50,738.12 349,990.96 2,637.81

PT Pyridam Farma Tbk Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,425.00 -14,095.19 -18,920.05 -25,164.96 -39,337.00

Competitive Comparison of PT Pyridam Farma Tbk's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, PT Pyridam Farma Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Pyridam Farma Tbk's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Pyridam Farma Tbk's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PT Pyridam Farma Tbk's EV-to-EBIT falls into.



PT Pyridam Farma Tbk EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-97,517 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PT Pyridam Farma Tbk  (ISX:PYFA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PT Pyridam Farma Tbk's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=61816 * ( 1 - 0% )/( (6397299 + 6070526)/ 2 )
=61816/6233912.5
=0.99 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6162584 - 356565 - ( 649760 - max(0, 2373228 - 1781948+649760))
=6397299

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5892993 - 429509 - ( 505423 - max(0, 2319861 - 1712819+505423))
=6070526

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

PT Pyridam Farma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-157348/( ( (1462220 + max(668178, 0)) + (1520817 + max(684620, 0)) )/ 2 )
=-157348/( ( 2130398 + 2205437 )/ 2 )
=-157348/2167917.5
=-7.26 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(545874 + 482877 + 92447) - (356565 + 0 + 96455)
=668178

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(614643 + 512222 + 77691) - (429509 + 0 + 90427)
=684620

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PT Pyridam Farma Tbk's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-97517.189/5276639.443
=-1.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PT Pyridam Farma Tbk EBIT Related Terms

Thank you for viewing the detailed overview of PT Pyridam Farma Tbk's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PT Pyridam Farma Tbk Business Description

Traded in Other Exchanges
N/A
Address
Jl. Gen. Sudirman No. Kav. 21, Sinarmas MSIG Tower 12th Floor, RT.10/RW.1, Kuningan, Karet, Setiabudi District, South Jakarta City, Jakarta, IDN, 12920
PT Pyridam Farma Tbk is an Indonesia-based company, engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through the following segments: Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. The company derives maximum revenue from Pharmaceutical Products and Toll Manufacturing Services. The company's products include consumer health, Derma, prescription, and biomedilab.

PT Pyridam Farma Tbk Headlines

No Headlines